# **Table of Contents**

**State/Territory Name: Washington** 

State Plan Amendment (SPA) #: 14-0018

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form (with 179-like data)
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services Seattle Regional Office 701 Fifth Avenue, Suite 1600, MS/RX-200 Seattle, WA 98104



#### Division of Medicaid & Children's Health Operations

## MAY 2 8 2014

Dorothy Frost Teeter, Director MaryAnne Lindeblad, Medicaid Director Health Care Authority P.O. Box 45502 Olympia, Washington 98504-5502

RE: Washington State Plan Amendment (SPA) Transmittal Number 14-0018

Dear Ms. Teeter and Ms. Lindeblad:

The Centers for Medicare & Medicaid Services (CMS) Pharmacy Team recently approved State Plan Amendment (SPA) 14-0018 effective January 1, 2014. This amendment proposes to remove barbiturates, benzodiazepines, and agents used to promote smoking cessation from the list of drugs the state Medicaid program may exclude from coverage or otherwise restrict in order to comply with the requirements of Section 2502(a) of the Affordable Care Act.

The state will receive an approval letter for this SPA from the CMS Pharmacy Team. The Seattle Regional Office is also providing an additional copy as we were the recipient of the original, signed amendment request and we maintain the official Washington State Plan. Enclosed you will find a copy of the official CMS form 179, amended page(s), and copy of the approval letter from the Pharmacy Team for your records.

If you have any questions concerning the Seattle Regional Office role in the processing of this SPA, please contact me, or have your staff contact Maria Garza at (206) 615-2542 or via email at maria.garza@cms.hhs.gov.

Sincerely,

Carol J.C. Peverly

Associate Regional Administrator Division of Medicaid and Children's Health

**Operations** 

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-26-12 Baltimore, Maryland 21244-1850



#### Center for Medicaid and CHIP Services

### Disabled and Elderly Health Programs Group

MAY 28 2014

Ms. MaryAnne Lindeblad
Medicaid Director
Office of Rules and Publications
Legal and Administrative Services
Health Care Authority
626 8<sup>th</sup> Ave. SE MS: 42716
Olympia, WA 98504-2716
Attn: Ann Myers

Dear Ms. Lindeblad:

We have reviewed Washington State Plan Amendment (SPA) 14-0018 received in the Seattle Regional Office on March 31, 2014. This amendment proposes to remove barbiturates, benzodiazepines, and agents used to promote smoking cessation from the list of drugs the state Medicaid program may exclude from coverage or otherwise restrict in order to comply with the requirements of Section 2502(a) of the Affordable Care Act.

Based on the information provided, we are pleased to inform you that consistent with the regulations at 42 CFR 430.20, SPA 14-0018 is approved with an effective date of January 1, 2014. A copy of the signed CMS-179 form, as revised, as well as the pages approved for incorporation into the Washington state plan, will be forwarded by the Seattle Regional Office.

If you have any questions regarding this amendment, please contact Terry Simananda at (410) 786-8144.

Sincerely,

Joseph L. Fine Acting Director Division of Pharmacy

cc: Carol Peverly, ARA, Seattle Regional Office Maria Garza, Seattle Regional Office

TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL	1. TRANSMITTAL NUMBER: 14-0018	2. STATE Washington	
FOR: HEALTH CARE FINANCING ADMINISTRATION	3. PROGRAM IDENTIFICATION: T SOCIAL SECURITY ACT (MEDIC		
TO: REGIONAL ADMINISTRATOR HEALTH CARE FINANCING ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES	HEALTH CARE FINANCING ADMINISTRATION DEPARTMENT OF HEALTH AND HUMAN SERVICES  April 1, 2014 January 1, 2014		
5. TYPE OF PLAN MATERIAL (Check One):			
	CONSIDERED AS NEW PLAN		
COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AME 6. FEDERAL STATUTE/REGULATION CITATION:	7. FEDERAL BUDGET IMPACT:	en amenament)	
Sections 1927(d)(2) and (7) of the Social Security Act	a. FFY 2014 \$0 b. FFY 2015 \$0		
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:	9. PAGE NUMBER OF THE SUPER OR ATTACHMENT (If Applicable		
Attachment 3.1-A page 32b	Attachment 3.1-B page 32b		
Att. 3.1-B page 32b (P&I)	Att. 3.1-A page 32b (F	2&1)	
10. SUBJECT OF AMENDMENT			
Remove Excluded Drugs in accordance with sect	cion 2502 of the ACA (	P&I)	
11. GOVERNOR'S REVIEW (Check One):  GOVERNOR'S OFFICE REPORTED NO COMMENT COMMENTS OF GOVERNOR'S OFFICE ENCLOSED NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL	☑ OTHER, AS SPE	CIFIED: Exempt	
12. SIGNATURE OF STATE AGENCY OFFICIAL:	16. RETURN TO:		
	Ann Myers Office of Rules and Publications		
13. TYPED NAME:	Legal and Administrative Services		
MARYANNE LINDEBLAD  14. TITLE:	Health Care Authority		
MEDICAID DIRECTOR 626 8th Ave SE MS: 42716			
15. DATE SUBMITTED:	Olympia, WA 98504-2716		
3-3.1-14	THE CHANGE ON THE	2.4.0.4.0	
17. DATE RECEIVED: 3/31/14	18. DATE APPROVED: 5/28/26	014	
PLAN APPROVED - ON			
19. EFFECTIVE DATE OF APPROVED MATERIAL: 01/01/2014	20. SIGNATURE OF REGIONAL OF		
21, TYPED NAME: Carol J.C. Peverly	22. TITLE: Associate Region Division of N	al Administrator	
23. REMARKS:	Children's		
4/07/2014: State authorizes P&I change to box 8,9,10 4/30/14: State authorizes P&I change	e to box 4		

#### STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

			State	WASHINGTO	N	
	(		,	ND SCOPE OF MEDICA OVIDED TO THE CATE		
12.	a.	Prescri	bed Drugs (contin	nued)		
				tropics, nasal preparational anti-inflammatories,		als,
		none	condition of sale	tpatient drugs which the that associated tests o the manufacturer or its	or monitoring service	
			No excluded dru	igs are covered.		

#### STATE PLAN UNDER TITLE XIX OF THE SOCIAL SECURITY ACT

		StateWASHINGTON
		AMOUNT, DURATION, AND SCOPE OF SERVICES PROVIDED TO THE MEDICALLY NEEDY GROUPS:ALL
12.	a.	Prescribed Drugs (continued)  laxatives, lipotropics, nasal preparations, topical antifungals, topical steroidal anti-inflammatories, topical antiparasitics
		none (vii) Covered outpatient drugs which the manufacturer seeks to require as a condition of sale that associated tests or monitoring services be purchased exclusively from the manufacturer or its designee
		No excluded drugs are covered.